Phase II randomized trial of sequentially administered CPT-11 [irinotecan] and mitomycin C in patients with advanced esophageal and stomach cancer.

Trial Profile

Phase II randomized trial of sequentially administered CPT-11 [irinotecan] and mitomycin C in patients with advanced esophageal and stomach cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2012

At a glance

  • Drugs Irinotecan (Primary) ; Mitomycin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2012 Companies (Pharmacia and Pfizer) added and actual patient number changed from 82 to 80 as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 28 Mar 2010 Results published in the Journal of Thoracic Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top